Latest News

AbbVie has 47 reasons for its $2B cancer immunotherapy partnership with I-Mab

The drugmaker said Friday that it would partner with Shanghai-based I-Mab on the development of lemzoparlimab, a drug that targets CD47. The antigen target, also known as the “don’t eat me” signal, is a growing area of immunotherapy, as illustrated by Gilead’s $4.9 billion buyout of Forty Seven in March.

Source link

Related posts

Dizziness Could Be A Sign of Dementia Risk


Eurofins Biomnis crée une capacité additionnelle de 15 000 tests par jour réalisés sous 24 heures


Greater prevalence of anal cancer precursors for women living with HIV than prior reports


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World